Loading…
Loading…
iShares Global Healthcare ETF provides broad sector coverage with a higher dividend yield than State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF has delivered stronger total returns over the last year but experiences significantly higher maximum drawdowns.
South Korean stocks fell sharply on Thursday as Brent crude held above $100 a barrel, pushing the KOSPI back below the 7,000 mark just a day after it reclaimed the level for the first time in more than a month. The benchmark was down 1.28% at 6,961.23 by late morning in Seoul.
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
The Vanguard Health Care ETF (VHT) is significantly cheaper to own than the iShares Global Healthcare ETF (IXJ). IXJ offers exposure to international companies, while VHT focuses more heavily on the U.S. market.
iShares Global Healthcare ETF offers a 1.4% dividend yield and lower price volatility than State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF focuses on U.S. biotechnology, resulting in a higher 1-year total return of 80.2% but a significantly deeper maximum drawdown.
iShares Global Healthcare ETF provides broader diversification with 110 holdings compared to 25 positions in VanEck Biotech ETF VanEck Biotech ETF delivered a 30.8% 1-year total return but has experienced a 39.9% historical maximum drawdown iShares Global Healthcare ETF offers a 1.5% trailing-12-month dividend yield and a longer history since its 2001 launch
IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield.
The iShares Global Healthcare ETF provides broader exposure with 110 holdings across various sub-sectors compared to the 26 positions in the VanEck Pharmaceutical ETF The VanEck Pharmaceutical ETF features a lower expense ratio of 0.36% and a higher trailing dividend yield of 2.00% While the iShares Global Healthcare ETF has experienced lower historical drawdowns, the VanEck Pharmaceutical ETF has delivered higher total returns over the last five years